4. Experts Believe Molnupiravir Is Better Than Remdesivir
Currently, remdesivir is the only antiviral drug for COVID-19, but some clinicians are not happy about it.
For instance, an investigation in Norway involving 23 hospitals noted that remdesivir “did not affect the degree of respiratory failure or inflammatory variables in plasma or serum5.” Another large study also pointed out that remdesivir does not increase a patient’s survival against COVID-196.
Molnupiravir, on the other hand, not only potentially reduces hospitalization and death by half, but it can also reach more people. Unlike remdesivir, which is infused in intravenous fluid usually during hospitalization, molnupiravir pills are prescribed early in the diagnosis.
5. Merck Has Plans to Manufacture Molnupiravir for Poorer Countries
Merck plans to seek Emergency Use Authorization from the US Food and Drug Administration as soon as possible, but it also plans to manufacture the antiviral in poorer countries.
In fact, Merck has already entered into licenses with 8 generic drug manufacturers in India in the hopes of supplying the drug to more than 100 countries.
6. Its Potential Is So Strong, Experts Asked To Stop the Trials
Another interesting thing about Molnupiravir is that an independent board of experts suggested stopping the trial because the antiviral’s benefits proved to be convincing. Also, the independent company said the FDA agreed to their suggestion.